Desktop Site
|
13 Sep 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Watch List
Get Quote
*
Notices
|
BSE SENSEX
82,890.94
-71.77
-0.09 %
Corporate Announcement
Security Code
532321
Company
Zydus Lifesciences Ltd
Exchange Received Time
10/09/2024 14:49:01
Exchange Disseminated Time
10/09/2024 14:49:01
Time Taken
00:00:00
Announcement under Regulation 30 (LODR)-Press Release / Media Release |
09/10/24 14:49
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).
Attachment
<< Back
Recently Viewed